Compumedics Limited · ASX:CMP

Compumedics — Shareholder Meeting (October 2015)

34 slides from Compumedics's shareholder meeting presentation, October 2015

  1. Slide 1: Compumedics Limited Corporate Presentation – September 2015

    Compumedics Limited Corporate Presentation – September 2015 1

  2. Slide 2: AGM - Agenda

    AGM - Agenda • Meeting Opens • Chairman's Address • Ordinary Business • Meeting Closes 2

  3. Slide 3: Investor Overview

    Investor Overview • FY 15 Highlights: $33.5m sales, revenue growth 9%, EBITDA $4.1m, NPAT $2.0m • Core business: now highly profitable and continues to grow with the full benefits of the earnings initiatives undertaken in recent years still to flow through. • New Product platform roll out to signifi

  4. Slide 4: Who is Compumedics?

    Who is Compumedics? • Compumedics is a leading global, innovative developer and manufacturer of medical devices for: – Diagnosing sleep disorders – Monitoring neurological disorders including long-term epilepsy monitoring (LTEM) – Highly sophisticated brain research – Ultrasonic monitoring of blood

  5. Slide 5: Directors & Executive Team Key Management

    Directors & Executive Team Key Management David Burton, Ph.D. Executive Chairman, CEO Founder, Tenure 26yrs NED Mr. David Lawson Mr. Alan Anderson Chief Financial Officer & Leading USA Attorney Company Secretary CMP Tenure : 11 yrs CMP Tenure 13 yrs Mr. Warwick Freeman Kerry Hubick, Ph.D. Mr. Christ

  6. Slide 6: A Tradition of Innovation

    A Tradition of Innovation Comperio DQ Summit IP SynAmps2 2004 2005 Somté 2003 2001 Siesta 802 Siesta 2000 2005 P Series 1994 S Series 1987 Somté PSG 2006 Neuvo LTM SynAmpsRT 2007 2008 CURRY6 Somnilink SPAP 2009 2010 Grael HD Somfit Somté PSG 2.0 2010 2015 2011 6

  7. Slide 7: Established Client Profile

    Established Client Profile 7

  8. Slide 8: Core Sleep and Brain Diagnostic Monitoring Business

    Core Sleep and Brain Diagnostic Monitoring Business 8

  9. Slide 9: FY15 Results

    FY15 Results • Revenue and profit figures in line with guidance • New sales orders taken in FY2015 were 19% higher than new sales orders taken in FY2014. Driven by growth in US, China and Europe. • Sales order backlog continues to decline, although late rush of sales orders received at 30 June 2015

  10. Slide 10: Revenue Composition at ≈$33m June 2015

    Revenue Composition at ≈$33m 30 June 2015 By geographic region By product/market Tech. Supply Service, Europe, USA, Items, 8% Sleep, 16% 34% 9% 28% Asia, 34% Brain Neuro, Blood Aust, Brain 12% Flow, 16% 21% Res, 21% Software upgrades 5 to 10% of system sales Compumedics sells directly to end-user cu

  11. Slide 11: Core Business Overview

    Core Business Overview • The core business has returned to strong operating profitability and is positioned for significant earnings growth in the years ahead • Cost reduction initiatives for the assembly and manufacture of key products are yet to fully flow through to the bottom line, expected to o

  12. Slide 12: International Growth – Geographic Expansion

    International Growth – Geographic Expansion • Expand our US sales force and management team to further build our market presence in the largest markets for sleep diagnostics and neurology. • Establish an office in Germany, a relatively untapped market for Compumedics to date. • Push into the Chinese

  13. Slide 13: Product Matrix

    Product Matrix Product Used for Bought by Average selling price Grael Sleep and Hospitals, doctors and USD17,500 neurology service providers Somte PSG Sleep Hospitals, doctors and USD10,000 service providers Siesta Sleep and Hospitals, doctors and USD18,000 neurology service providers Neuvo LTM Neur

  14. Slide 14: Historical Full Year Revenues

    Historical Full Year Revenues 12 months to 30 June Shipped and invoiced 40.0 35.0 30.0 25.0 20.0 15.0 10.0 5.0 0.0 FY2013 FY2014 FY2015 F'cast FY2016 H1 Rev F'Cast Rev

  15. Slide 15: Historical Full Year Earnings

    Historical Full Year Earnings 12 months to 30 June NPAT EBITDA 3.5 6 3 5 2.5 2 4 1.5 1 3 0.5 2 0 -0.5 FY2013 FY2014 FY2015 Fcast 1 FY2016 -1 0 -1.5 FY2013 FY2014 FY2015 Fcast -2 FY2016 NPAT F'Cast NPAT EBITDA F'Cast EBITDA Full year EBITDA for FY2016 is estimated between $4.5m and $5.5m. Excluding M

  16. Slide 16: Employee Composition at ≈120 staff

    Employee Composition at ≈120 staff 30 June 2015 By geographic region By function Mid Admin Asia, Sales & East, & Fin, Quality, 3% Mark, 1% USA & 2% Manuf, 14% 23% LA, 20% 31% Europe, 30% Service, Aust, R&D, 19% 35% 22% Compumedics has its Head Office in Melbourne, Australia with additional offices i

  17. Slide 17: Tide turning post GFC and high AUD

    Tide turning post GFC and high AUD 45,000 5,000 40,000 4,000 35,000 3,000 30,000 25,000 2,000 20,000 1,000 15,000 - 10,000 5,000 -1,000 - -2,000 2009 2010 2011 2012 2013 2014 2015 Revenues EBITDA 1.2000 1.0000 0.8000 0.6000 0.4000 0.2000 0.0000 2009 2010 2011 2012 2013 2014 2015 AUD/USD Exchange rat

  18. Slide 18: Growth Drivers – Core business

    Growth Drivers – Core business • Compumedics/NeuroScan LTEM innovative brain analysis software and high performance amplifiers are unrivalled world class technology • We have >20,000 systems installed worldwide. Strong reputation and brand name. Customers like buying from Compumedics. • Earnings ini

  19. Slide 19: Earnings improvement activities

    Earnings improvement activities • Outsourcing Manufacturing – lower cost regions of China and Taiwan • EEG cap production completely relocated at Dec 14 and Grael production to be completed by Dec 2015 • Offshore or specialist purchasing houses to increase quality and drive down costs. Grael and Som

  20. Slide 20: Growth Strategies – core business

    Growth Strategies – core business USA Clinical Sales Force Expansion More sales representatives > more revenue Past for both sleep and neurology USD4.5m FY2015 - Now USD6.4m FY2016 USD10.0m FY2017 USD15.0m

  21. Slide 21: China - We are the number 1 Premier Supplier

    China - We are the number 1 Premier Supplier Compumedics Clients in China China Sales – USD’s 10 5 0 FY12 FY13 FY14 FY15 21

  22. Slide 22: Strategic Value Realisation

    Strategic Value Realisation 22

  23. Slide 23: Strategic value realisation

    Strategic value realisation The company is currently considering options to simplify its business and unlock significant value for shareholders by: • Spinning out its Germany based DWL Transcranial Doppler (TCD) ultrasound blood flow business • Spinning out its Brain Research business (NeuroScan) 23

  24. Slide 24: DWL Spin out opportunity

    DWL Spin out opportunity • DWL is the founding business and global leader in TCD ultrasound. • Short term growth opportunities in 3D Transcranial Colour Doppler (TCCD)/Duplex Imaging • Medium term growth opportunities in TBI and Stroke Market • 3D TCCD is a US$900m vs DWL’s current market of $US30m.

  25. Slide 25: Brain Research Spin Out Opportunity

    Brain Research Spin Out Opportunity • Growth outlook – significant for Neuroscan CURRY – World’s best of class brain analysis software • Enormous neurology devices demand – est. $7bn pa by 2017 up from $2bn in 2010 • CURRY multi modal brain analysis technology – traditional research market - $50m pa

  26. Slide 26: eHealth – Next Phase in Compumedics Growth

    eHealth – Next Phase in Compumedics Growth 26

  27. Slide 27: Medical Innovations – eHealth

    Medical Innovations – eHealth • Compumedics is developing eHealthMedics, an online professional sleep services platform • Sleep diagnostics is traditionally delivered as a lab-based (equipment intense) or Home Sleep Testing service eHealthMedics has re-architected its solution such that the sleep mo

  28. Slide 28: eHealthMEDICS - Competitive Advantage

    eHealthMEDICS - Competitive Advantage • The scalability and cost efficiencies of eHealthMedics vs traditional sleep diagnostics allow the service to accommodate very large sleep-disordered populations, even in regions where private or public health insurance is limited or non-existent (eg China – a

  29. Slide 29: eHealthMEDICS – Making Progress

    eHealthMEDICS – Making Progress • eHealthMedics has already locked in excess of $10m of forward orders over the next three years (primarily in China) for its professional services platform. Initial pilot sites commence in May and June this year • Operational systems have been developed for the cloud

  30. Slide 30: eHealthMEDICS - eHealth services platform leveraging core competencies

    eHealthMEDICS - We bring to the table a eHealth services platform that leverages core competencies built over 25 years mHealth Product Ecosystem: Required Competencies • Inc. medical data security [traditional business] (FDA, CE, TGA compliant, US est. 1987 HIPPS) • Medical grade Cloud • Established

  31. Slide 31: Investor Summary

    Investor Summary • Core business continues to grow • International sales force expansion, neurology market opportunity and earnings improvement initiatives to continue to drive growth of core business • Compumedics remains committed to continuing to deliver superior returns to shareholders • e-Healt

  32. Slide 32: Ordinary Business

    Ordinary Business • Item 1 Financial Statements and Reports • Item 2 Re-election of Director – David Lawson • Item 3 Adoption of Remuneration Report (non-binding resolution) 32

  33. Slide 33: Meeting Closes

    Meeting Closes Refreshments are available in the main reception area, where additional questions and discussion are encouraged, for those who are interested. 33

  34. Slide 34: OneMedForum 2011 - San Francisco

    OneMedForum 2011 - San Francisco Wednesday 12 January 2011 34

Compumedics — Shareholder Meeting (October 2015) on 6ix